In the field of medicine, acting too quickly can lead to catastrophic results. A prime example is the thalidomide scandal associated with morning sickness. Pregnant animals were never tested, reflecting the risks of changing procedures based on insufficient evidence. However, slow responses can also pose dangers, as seen with the reliance on body mass index (BMI).

For years, BMI, a straightforward calculation based on weight and height, has proven inadequate for distinguishing between fat and muscle or accounting for global variations. While it is a quick and cost-effective measure, its prolonged use has misclassified millions, leading to denied fertility treatments and surgeries.

Fortunately, alternative measurements are gaining traction. In a pivotal move last year, The Lancet urged that BMI not be the sole metric for assessing obesity, a recommendation embraced by 75 international medical organizations.

This shift indicates a potential resolution to the medical inertia stemming from insufficient evidence, lack of consensus, and leadership necessary for progress, especially after the errors of the 20th century.

The rapid development of COVID-19 vaccines, which saved approximately 14 million lives within their first year, serves as an exemplary model of fast, evidence-based action in healthcare.

This type of proactive response is crucial in various underdeveloped healthcare sectors, including enhanced menopause care, innovative psychiatric treatments, additional male contraception options, and new antibiotics.

While caution is essential, it’s crucial to act swiftly without compromising safety and effectiveness.